Literature DB >> 20011736

Fulminant legionellosis in two patients treated with infliximab for Crohn's disease: case series and literature review.

Adam Hofmann1, Yanick Beaulieu, Francis Bernard, Philippe Rico.   

Abstract

Two cases of fulminant pulmonary legionellosis, complicated by prolonged intensive care unit stays and acute respiratory distress syndrome, and who were recently treated with infliximab for Crohn's disease, are described. A review of the literature revealed three additional cases in patients with inflammatory bowel disease, and a total of 22 cases of Legionella pneumophila pneumonia in the context of treatment with antitumour necrosis (TNF)-alpha medications. The median age of the patients was 49 years, and men and women were affected equally. The case fatality rate was 14% (three of 22). Early recognition and treatment of this anti-TNF-alpha-related complication would likely result in reduced mortality and morbidity. Physicians prescribing anti-TNF-alpha drugs should be aware of this association.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20011736      PMCID: PMC2805520          DOI: 10.1155/2009/836938

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  11 in total

1.  [Legionellosis in patient treated with infliximab].

Authors:  C Albert; F Vandenbos; O Brocq; D Carles; L Euller-Ziegler
Journal:  Rev Med Interne       Date:  2004-02       Impact factor: 0.728

2.  Fatal fulminant legionnaires' disease in a patient with severe erythodermic psoriasis treated with infliximab after long-term steroid therapy.

Authors:  K Eisendle; P Fritsch
Journal:  Br J Dermatol       Date:  2005-03       Impact factor: 9.302

3.  Tuberculosis and Legionella pneumophila pneumonia in a patient receiving anti-tumour necrosis factor-alpha (anti-TNF-alpha) treatment.

Authors:  G Mancini; L Erario; R Gianfreda; A Oliva; A P Massetti; C M Mastroianni; V Vullo
Journal:  Clin Microbiol Infect       Date:  2007-08-17       Impact factor: 8.067

4.  Severe Legionella pneumophila pneumonia following infliximab therapy in a patient with Crohn's disease.

Authors:  Florian Beigel; Matthias Jürgens; Levent Filik; Lutz Bader; Christian Lück; Burkhard Göke; Thomas Ochsenkühn; Stephan Brand; Julia Seiderer
Journal:  Inflamm Bowel Dis       Date:  2009-08       Impact factor: 5.325

Review 5.  Legionellosis.

Authors:  J E Stout; V L Yu
Journal:  N Engl J Med       Date:  1997-09-04       Impact factor: 91.245

6.  Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists.

Authors:  F Tubach; P Ravaud; D Salmon-Céron; N Petitpain; O Brocq; F Grados; J C Guillaume; J Leport; A Roudaut; E Solau-Gervais; M Lemann; X Mariette; O Lortholary
Journal:  Clin Infect Dis       Date:  2006-10-16       Impact factor: 9.079

7.  Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.

Authors:  W G Dixon; K Watson; M Lunt; K L Hyrich; A J Silman; D P M Symmons
Journal:  Arthritis Rheum       Date:  2006-08

8.  A case of legionellosis during treatment with a TNFalpha antagonist.

Authors:  Marielle J Wondergem; Alexandre E Voskuyl; Michiel A van Agtmael
Journal:  Scand J Infect Dis       Date:  2004

Review 9.  Legionella pneumophila pathogenesis and immunity.

Authors:  Herman Friedman; Yoshimasa Yamamoto; Thomas W Klein
Journal:  Semin Pediatr Infect Dis       Date:  2002-10

10.  Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up.

Authors:  A Kohn; M Daperno; A Armuzzi; M Cappello; L Biancone; A Orlando; A Viscido; V Annese; G Riegler; G Meucci; M Marrollo; R Sostegni; A Gasbarrini; S Peralta; C Prantera
Journal:  Aliment Pharmacol Ther       Date:  2007-09-01       Impact factor: 8.171

View more
  6 in total

1.  Crohn's disease as an immunodeficiency.

Authors:  Bu'Hussain Hayee; Farooq Z Rahman; Gavin Sewell; Andrew M Smith; Anthony W Segal
Journal:  Expert Rev Clin Immunol       Date:  2010-07       Impact factor: 4.473

2.  Legionella pneumophila type II secretion dampens the cytokine response of infected macrophages and epithelia.

Authors:  Kessler McCoy-Simandle; Catherine R Stewart; Jenny Dao; Sruti DebRoy; Ombeline Rossier; Paul J Bryce; Nicholas P Cianciotto
Journal:  Infect Immun       Date:  2011-03-07       Impact factor: 3.441

Review 3.  Viewing Legionella pneumophila Pathogenesis through an Immunological Lens.

Authors:  Xin Liu; Sunny Shin
Journal:  J Mol Biol       Date:  2019-07-25       Impact factor: 6.151

4.  When Diarrhea Can Become Deadly: Legionnaires' Disease Complicated by Bowel Obstruction.

Authors:  Wesley Prichard; Laurel Fick
Journal:  Case Rep Gastroenterol       Date:  2016-12-20

5.  Extreme Rhabdomyolysis, Acute Renal Failure, and Protracted Ileus in a Case of Legionella Pneumonia.

Authors:  C Laivier; M-O Bleuze; P Hantson; J Devos
Journal:  Case Rep Crit Care       Date:  2019-01-29

6.  Legionella pneumophila serotype 1 pneumonia in patient receiving adalimumab.

Authors:  Terry C Wuerz; Owen Mooney; Yoav Keynan
Journal:  Emerg Infect Dis       Date:  2012-11       Impact factor: 6.883

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.